Dr. Richard Isaacson was featured by CNN following the FDA’s accelerated approval of Leqembi (lecanemab), one of the first Alzheimer’s treatments shown to slow cognitive decline in people with early-stage disease. While calling the approval an important milestone, Dr. Isaacson emphasized that the medication is not appropriate for every patient and should be prescribed only after careful evaluation, personalized risk assessment, and ongoing monitoring.

Dr. Isaacson explained that identifying the right candidates for treatment requires confirmation of Alzheimer’s pathology, consideration of genetic risk factors such as APOE4, and thoughtful discussions about potential benefits and risks, including brain swelling and bleeding. He described Leqembi as “another tool” in the fight against Alzheimer’s disease while underscoring the continued importance of precision medicine, early detection, and comprehensive prevention strategies alongside emerging therapies.

Read the full CNN article to learn more about the FDA approval of Leqembi and what it means for people living with early Alzheimer’s disease.